Free 7-day Trial
All Articles and Columns »

CELSCISci Corp Reports Operating Results (10-Q/A)

January 29, 2010 | About:
insider

10qk

18 followers
CELSCISci Corp (CVM) filed Amended Quarterly Report for the period ended 2008-12-31.

Celscisci Corp has a market cap of $115.8 million; its shares were traded at around $0.71 with and P/S ratio of 1428.6.
This is the annual revenues and earnings per share of CVM over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of CVM.


Highlight of Business Operations:

During the three-month period ended December 31, 2008 and 2007, the Company used

cash totaling $612,311 and $1,653,800, respectively. For the three months ended

December 31, 2008 and 2007, cash used in operating activities totaled $1,159,800

and $1,440,094. For the three months ended December 31, 2008 and 2007, cash

provided by financing activities totaled $114,922 and cash used by financing

activities totaled $180,597, respectively. Private placement proceeds of

$499,982 and receipt of the short-term loan of $100,000 provided funds. The

repayment of convertible notes ($270,000), financing costs (15,060) and the

repayment of the short-term loan ($200,000) was used in financing activities

during the three months ended December 31, 2008. For the three months ended

December 31, 2007, cash was provided by financing was from the exercise of

employee options ($14,403). Repayment of convertible notes of $195,000 used cash

in financing activities. Cash provided by investing activities was $432,567 and

$33,109 was used in investing activities for the three months ended December 31,

2008 and 2007, respectively. The use of cash in investing activities consisted

of purchases of equipment and legal costs incurred in patent applications and,

for the three months ended December 31, 2008, the sale of the final $200,000 in

ARPs.





The Company has two partners who have agreed to participate in and pay for part

of the Phase III clinical trial for Multikine. However in light of the current

capital market environment, the Company believes it is prudent not to start the

Phase III clinical trial until it has firm commitments in the form of

partnerships and/or money raised for a substantial amount of cash to support the

Phase III clinical trial. In the meantime, the Company will operate at

significantly reduced cash expenditure levels and additional cash may be raised

by offering contract manufacturing services to the pharmaceutical industry in

its new manufacturing facility. The Company expects that it will need to raise

additional capital in fiscal year 2009 in the form of corporate partnerships

and/or equity financings to support its operations at its current rate. The

Company is currently working towards a transaction which it expects to complete

in fiscal 2009 which will finance its Phase III clinical trial of Multikine. The

Company believes that it will be able to obtain additional financing since

Multikine is a Phase III product designed to treat cancer, an area that

pharmaceutical companies are increasingly targeting. The Company is working on a

sale-leaseback program for the equipment it owns which would provide the Company

approximately $1.5 million in additional cash. It is important to note that the

Company's expenditures for fiscal year 2008 included several very large

non-recurring expenses that amounted to several million dollars, mostly related

to the build out of the manufacturing facility. These expenses will not recur in

fiscal year 2009, thereby reducing the Company's expenditures significantly.

Beyond those savings the Company has also made other very significant cuts in

its expenditures. In addition, the Company has put in place a $5 million Equity

Line of Credit (see Note E). With this Equity Line of Credit in place the

Company believes it will have the required capital to continue operations into

March 2010. However, if necessary the Company can make further reductions in

expenditures by a reduction in force or by implementation of a salary reduction

program.



The Company has determined that the convertible debt holders of the Series K

Notes may require repayment of the entire remaining principal balance at any

time after August 4, 2009. This debt can be paid in stock and may not require a

cash payment. In addition, in December 2008, CEL-SCI was not in compliance with

certain lease requirements (i.e., failure to pay an installment of Base Annual

Rent). However, the landlord has not declared the Company formally in default

under the terms of the lease and has renegotiated the lease. The landlord

currently has the right to declare the Company in default if the Company fails

to pay any installment of the Base Annual Rent when such failure continues for a

period of 5 business days after the Company's receipt of written notice thereof

from the Landlord, provided that if the Company fails to pay any of the

foregoing within 5 business days more than two (2) times in any twelve (12)

month period during the lease term, the Landlord shall not be required to

provide the Company with any further notice and the Company shall be deemed to

be in default. Per the renegotiated lease (see Note L), the landlord has agreed

to defer 3 months (December - February) of rent which will be paid back

incrementally only after future financings. CEL-SCI then will begin paying basic

annual rent starting in March 2009 and failure to pay the entire monthly

installment thereafter shall constitute a material default under the lease. In

return, CEL-SCI extended 3,000,000 warrants by one year and repriced these

warrants from $1.25 to $0.75 and the landlord was issued an additional 787,000

warrants at $0.75. Both warrants expire on January 26, 2014.



During the three-month period ended December 31, 2008, general and

administrative expenses decreased by $730,623 compared to the three-month period

ended December 31, 2007. This decrease is caused by the Company having extended

and repriced options during the three-month period ended December 31, 2007 of

$465,008 and the expensing of stock issued to employees in the three-month

period ended December 31, 2007 of $378,350 compared to a cost of employee stock

issued in prior periods but expensed in the three-month period ended December

31, 2008 of only $40,686, a decrease of $337,664. This decrease from December

31, 2007 to December 31, 2008 was partially offset by higher insurance costs of

approximately $16,500.



The interest expense of $84,616 for the three months ended December 31, 2008 was

composed of three elements: 1) amortization of the Series K discount ($43,649),

2) interest paid and accrued on the Series K debt ($40,154) and 3) margin

interest ($813). This is a decline of approximately $59,400 from the three

months ended December 31, 2007 because of the lower balance of Series K debt.



$3,150,000 towards the remodeling costs, which will be recouped by reductions in

the annual base rent of $303,228 in years six through twenty of the lease. In

January 2008, the Company signed a second amendment to the lease. In accordance

with the lease, on February 8, 2008, the Company paid an additional $1,295,528

toward the remodeling costs and a further $518,790 to pay for lab equipment. In

addition, in April 2008, an additional $288,474 was paid for the completion of

the facility. The Company took possession of the manufacturing facility in

October, 2008.



Read the The complete Report

About the author:

10qk
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 5.0/5 (2 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide